MMP26 Antibody (N_term)
- Known as:
- MMP26 Antibody (N_term)
- Catalog number:
- AP6207a
- Product Quantity:
- 0.1 mg
- Category:
- -
- Supplier:
- Abgen
- Gene target:
- MMP26 Antibody (N_term)
Related genes to: MMP26 Antibody (N_term)
- Gene:
- MMP26 NIH gene
- Name:
- matrix metallopeptidase 26
- Previous symbol:
- -
- Synonyms:
- endometase, MGC126590, MGC126592
- Chromosome:
- 11p15.4
- Locus Type:
- gene with protein product
- Date approved:
- 2000-12-13
- Date modifiied:
- 2016-10-05
Related products to: MMP26 Antibody (N_term)
Related articles to: MMP26 Antibody (N_term)
- Matrilysins and stromelysins play a vital role in cancer, facilitating tumor invasion and metastasis. The aim of this study was to investigate the diagnostic significance of selected matrilysins and stromelysins in comparison to routine tumor markers in gynecological malignancies, relative to a control group (benign tumors and healthy women). Preoperative plasma levels of selected metalloproteinases were determined using ELISA, while levels of CA125, SCC-Ag, and HE4 by CMIA. In endometrial and cervical cancers, matrilysins (MMP-7 and MMP-26) exhibited higher diagnostic utility than routine markers. Similarly, all stromelysins in cervical cancer outperformed CA125; furthermore, MMP-10 also outperformed SCC-Ag, achieving the highest diagnostic utility among all parameters tested in cervical cancer. For ovarian cancer, diagnostic utility remained highest for routine markers. In endometrial and cervical cancers, the AUCs for all studied parameters exceeded those of standard markers, while in ovarian cancer, MMP-7 had an AUC higher than HE4 and comparable to CA 125. Combined analysis of the studied parameters in diagnostic panels demonstrated that their introduction into routine diagnostics could provide tangible benefits in the detection of malignant gynecological lesions, especially the combination of MMP-7 or MMP-10 with routine markers. These results indicate the usefulness and high diagnostic power of selected MMPs in the detection of these malignancies. - Source: PubMed
Publication date: 2026/06/20
Gacuta EwaZajkowska MonikaŁawicki MichałUrban JuliaLaudański PiotrZbucka-Krętowska MonikaJózefczak Mateusz AntoniGuszczyn TomaszŁawicki PawełDubatówka MarlenaKicman AleksandraŁawicki Sławomir - Prostate Cancer (PCa) is the most common male malignancy, and its initiation and progression may be influenced by environmental pollutants such as di(2-ethylhexyl) phthalate (DEHP). - Source: PubMed
Publication date: 2026/06/12
Chen JinjiChen JianlinHuang JunmingChen ShaohuaFeng Guanzheng - : Detection of cervical lesions is crucial for effective prevention and treatment. Therefore, the search for new diagnostic markers is extremely important. This study aimed to evaluate the concentration and diagnostic utility of selected matrix metalloproteinases (MMPs) as novel biomarkers. : The study group consisted of 320 participants: 160 patients with cervical cancer (CC), 100 patients with cervical dysplasia (CD), and 60 healthy controls (HC). MMPs were determined by an ELISA (Enzyme-Linked Immunosorbent Assay), and CA 125 and SCC-Ag by a CMIA (chemiluminescent microparticle immunoassay). : Our study revealed significantly higher concentrations of MMP-7 and MMP-10 in the CC and CD groups compared to healthy controls. Interestingly, concentrations of these two parameters increased with the advancement of the disease. In the case of MMP-3, the highest concentrations were observed in the CD group, moderate concentrations in the group with diagnosed CC, and the lowest in the group of healthy women. Notably, the concentration of this parameter in the CC group decreased with increasing disease advancement. In the case of MMP-26, the highest concentrations, which increased with advancement, were observed in CC, moderate concentrations in HC, and the lowest in the group of women with CD. The highest diagnostic usefulness among all the parameters was shown for MMP-7 (sensitivity (SE): 96%; specificity (SP): 94.14%; positive predictive value (PPV): 92.26%; negative predictive value (NPV): 85.46%; area under the curve (AUC): 0.9878) and MMP-10 (SE: 90.25%; SP: 80.05%; PPV: 92.15%; NPV: 88.45%; AUC: 0.9404). : All parameters presented significant differences between the concentrations obtained in the CC group and the CD group, which may indicate their usefulness not only in the diagnosis of cervical cancer, but also in the possible differentiation between benign and malignant lesions. - Source: PubMed
Publication date: 2025/11/27
Gacuta EwaŁawicki MichałGrabowska HannaŁawicki PawełKulesza MonikaKicman AleksandraZajkowska MonikaLaudański PiotrŁawicki Sławomir - Endometrioid ovarian cancer (EnOC) is a late-diagnosed gynecological cancer with limited diagnostic methods that, when detected at an early stage, has a good prognosis. This study is the first to evaluate the plasma concentrations and diagnostic utility of selected metalloproteinases as new biomarkers for EnOC. : The study group consisted of 50 newly diagnosed, untreated patients with EnOC; the control group consisted of 25 patients with endometrial cysts, 25 patients with serous cysts, and 50 healthy women. Selected matrilysins and stromelysins were determined by means of immunoenzymatic assay (ELISA) and routine markers (CA125 and HE4) using the chemiluminescence (CMIA) method. Higher levels of MMP-7, MMP-10, MMP-11, and MMP-26 were found in patients with EnOC when compared to healthy women. Concentrations of MMP-7, MMP-10, and MMP-11 were higher in women with EnOC when compared to benign lesions (BL). The highest SE (98.55%), NPV (95.41%), ACC (57.58%), and AUC (0.9658) values were obtained for MMP-7. High values of diagnostic parameters were also obtained for MMP-11 and MMP-26. These results suggest the usefulness of MMP-7, MMP-26, and MMP-11 in the diagnosis of EnOC as new biomarkers in this pilot study. - Source: PubMed
Publication date: 2025/09/02
Gacuta EwaKicman AleksandraŁawicki PawełŁawicki MichałKulesza MonikaMalinowski PawełChlabicz MarcinZajkowska MonikaŁawicki Sławomir - To explore the application value of joint detection of serum neutrophil-to-lymphocyte ratio (NLR), prostate-specific antigen (PSA) and MMP26 in differentiating prostate cancer (PCa) from benign prostatic hyperplasia (BPH). - Source: PubMed
Wang Yi-JinLi QiangFu Guang-Bo